Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1002/cpt.1857

http://scihub22266oqcxt.onion/10.1002/cpt.1857
suck pdf from google scholar
32302411!7262099!32302411
unlimited free pdf from europmc32302411    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32302411  :  Publisher
PDF vom PMID32302411

suck abstract from ncbi

pmid32302411
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 #MMPMID32302411
  • Damle B; Vourvahis M; Wang E; Leaney J; Corrigan B
  • Clin Pharmacol Ther 2020[Aug]; 108 (2): 201-211 PMID32302411show ga
  • Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for the treatment of viral infections, and there is no well-controlled, prospective, randomized clinical evidence to support AZ therapy in coronavirus disease 2019 (COVID-19). Nevertheless, there are anecdotal reports that some hospitals have begun to include AZ in combination with hydroxychloroquine or chloroquine (CQ) for treatment of COVID-19. It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in combination with other agents, to ensure safe study conduct and to increase the probability of achieving definitive answers regarding efficacy of AZ in the treatment of COVID-19. The safety profile of AZ used as an antibacterial agent is well established.(1) This work assesses published in vitro and clinical evidence for AZ as an agent with antiviral properties. It also provides basic CP information relevant for planning and initiating COVID-19 clinical studies with AZ, summarizes safety data from healthy volunteer studies, and safety and efficacy data from phase II and phase II/III studies in patients with uncomplicated malaria, including a phase II/III study in pediatric patients following administration of AZ and CQ in combination. This paper may also serve to facilitate the consideration and use of a priori-defined control groups for future research.
  • |Antiviral Agents/*pharmacology/therapeutic use[MESH]
  • |Azithromycin/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use[MESH]
  • |Betacoronavirus/*drug effects/pathogenicity[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Coronavirus Infections/drug therapy[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/pharmacology[MESH]
  • |Lung/drug effects[MESH]
  • |Microbial Sensitivity Tests[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    201 2.108 2020